A cautionary tale that Europe can’t afford to ignore
The pharma giant ranks No. 116 on the Fortune 500 Europe list and appears on the latest World’s Most Admired Companies list.
Outsourcing-pharma2d
Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
Why Novo Nordisk surged 14% on new weight-loss drug results
Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
ENDPOINTS NEWS6d
No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al
Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical ...
Novo Nordisk A/S: Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...